CN114217068A - Detection reagent strip for interleukin-6 and application thereof - Google Patents
Detection reagent strip for interleukin-6 and application thereof Download PDFInfo
- Publication number
- CN114217068A CN114217068A CN202111250811.3A CN202111250811A CN114217068A CN 114217068 A CN114217068 A CN 114217068A CN 202111250811 A CN202111250811 A CN 202111250811A CN 114217068 A CN114217068 A CN 114217068A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- magnetic
- reagent strip
- hole
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940100601 interleukin-6 Drugs 0.000 title claims abstract description 47
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 43
- 102000004889 Interleukin-6 Human genes 0.000 title claims abstract description 35
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 35
- 238000001514 detection method Methods 0.000 title claims abstract description 34
- 239000011324 bead Substances 0.000 claims abstract description 51
- 239000000376 reactant Substances 0.000 claims abstract description 19
- 238000004140 cleaning Methods 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 230000005284 excitation Effects 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 239000004005 microsphere Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 230000008105 immune reaction Effects 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 239000002245 particle Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000007865 diluting Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- -1 casein sodium salt Chemical class 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Abstract
The invention relates to a detection reagent strip for interleukin-6, which comprises a plurality of hole sites arranged side by side; and at least one of a magnetic rod sleeve, a coated antibody magnetic bead, a labeled reactant, a magnetic bead cleaning solution or a pre-excitation solution is arranged in the hole sites and used for sleeving the magnetic rod. The interleukin-6 detection reagent strip combines a chemiluminescence technology with immunomagnetic particles, and provides a reaction system close to homogeneous phase; compared with the prior art, the method has higher detection sensitivity and specificity, and achieves better performance parameters.
Description
Technical Field
The invention relates to the field of immunoassay, in particular to a detection reagent strip for interleukin-6 and application thereof.
Background
Interleukins are a class of cytokines that are produced by and act on a wide variety of cells. Originally, cytokines were produced by leukocytes and were regulated among leukocytes. The cell factor is named uniformly and has basically definite molecular structure and biological function and important regulation function, and belongs to the same category as the blood cell growth factor. The two are mutually coordinated and interacted to jointly complete the functions of hematopoiesis and immunoregulation. Interleukins play important roles in transmitting information, activating and regulating immune cells, mediating T, B cell activation, proliferation and differentiation, and in inflammatory responses.
Interleukin-6 is a pleiotropic cytokine that can assist in the early diagnosis of acute inflammation in clinical emergency patients. Interleukin-6 is produced by monocytes and macrophages stimulated by Toll-like receptors during the early stages of infectious inflammation. In non-infectious inflammation, such as burns or traumatic injuries, it may also be produced by cells stimulated by Toll-like receptors.
At present, the clinical detection of interleukin-6 mainly comprises an ELISA method, a chemiluminescence method, an immunofluorescence method and the like.
Although the ELISA method is clinically used for nearly twenty years, the ELISA method still has some fatal defects, such as poor quantitative accuracy, long operation time, low automation degree, easy interference and the like; the chemiluminescence method has high sensitivity and good specificity, but a general chemiluminescence machine is large because of a complex liquid path cleaning system, and even if the machine is reduced by optimized design, the daily maintenance of the machine is difficult.
Therefore, a reagent strip for detecting interleukin-6 and its application are needed.
Disclosure of Invention
The invention aims to provide a detection reagent strip for interleukin-6 and application thereof, aiming at the defects in the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides a detection reagent strip for interleukin-6, which comprises a plurality of hole sites arranged side by side; and at least one of a magnetic rod sleeve, a coated antibody magnetic bead, a labeled reactant, a magnetic bead cleaning solution or a pre-excitation solution is arranged in the hole sites and used for sleeving the magnetic rod.
Preferably, the coated antibody magnetic beads are magnetic microspheres coated with anti-interleukin-6 monoclonal antibodies.
Preferably, the labeling reactant is an anti-interleukin-6 monoclonal antibody labeled with acridinium ester.
Preferably, the magnetic bead cleaning solution is Tris-HCl buffer solution containing Tween and a preservative.
Preferably, the pre-excitation liquid is a nitric acid solution containing hydrogen peroxide.
Preferably, a magnetic rod sleeve for sleeving a magnetic rod is arranged in the hole position 0 of the detection reagent strip; a coated antibody magnetic bead is arranged in the No. 3 hole; a labeled reactant is arranged in the No. 6 hole; magnetic bead cleaning liquid is arranged in the No. 7-9 hole sites; a pre-excitation liquid is arranged in the No. 10 hole.
In a second aspect of the present invention, there is provided a test method using the test reagent strip as described above, comprising the steps of:
s1, adding the sample to a No. 4 hole site, simultaneously transferring the coated antibody magnetic beads and the labeled reactant to the No. 4 hole site, and combining the coated antibody magnetic beads and the labeled reactant into an immune complex through immune reaction, wherein the immune complex is a magnetic microsphere coated by an anti-interleukin-6 monoclonal antibody, an interleukin-6 antigen and an anti-interleukin-6 monoclonal antibody labeled with acridinium ester;
s2, transferring the immune complexes to the No. 7-9 hole sites in sequence to remove the unbound antigen or the labeled reactant through washing;
s3, transferring the immune complex to the No. 10 hole site, and adding an excitation liquid to determine the luminous value of the chemiluminescence reaction.
The third aspect of the present invention provides a detection kit containing the detection reagent strip as described above, further comprising a calibrator.
Preferably, the calibrator is a BSA solution containing interleukin-6 antigen.
By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:
the interleukin-6 detection reagent strip combines a chemiluminescence technology with immunomagnetic particles, and provides a reaction system close to homogeneous phase; compared with the prior art, the method has higher detection sensitivity and specificity, and achieves better performance parameters; the used detection technology is a full-automatic random detection system, based on a magnetic particle chemiluminescence technology, a magnetic rod extraction technology is used, a single-person detection mode which can be used immediately is adopted, the flexibility is high, different tests can be simultaneously carried out, and the operation can be tested singly, so that shorter detection time is obtained, the product cost is greatly reduced, the full automation is realized, a disposable gun head is matched for use, the pollution can be avoided, the manual operation from sampling to result generation is reduced, and the detection safety and the accuracy are improved.
Drawings
FIG. 1 is a schematic structural diagram of the interleukin-6 detection reagent strip of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict.
The invention is further described with reference to the following drawings and specific examples, which are not intended to be limiting.
Example 1
The embodiment provides an interleukin-6 detection reagent strip, which comprises a plurality of hole sites arranged side by side; and at least one of a magnetic rod sleeve, a coated antibody magnetic bead, a labeled reactant, a magnetic bead cleaning solution or a pre-excitation solution is arranged in the hole sites and used for sleeving the magnetic rod.
The magnetic rod sleeve is matched with a special up-draft magnetic bead transfer gun, when interleukin-6 is detected, the magnetic rod can penetrate into liquid to quickly extract magnetic beads, and the magnetic rod sleeve is a disposable consumable material, so that the magnetic rod can be prevented from being polluted by the magnetic beads, and meanwhile, the magnetic beads are easy to elute; all reagents are respectively stored in corresponding hole sites in a sealing mode by adopting a heat sealing film technology, so that reagent holes are effectively prevented from being mixed, and the transportation problem is solved.
Wherein the coated antibody magnetic beads are magnetic microspheres coated with anti-interleukin-6 monoclonal antibodies; the labeling reactant is an anti-interleukin-6 monoclonal antibody labeled with acridinium ester; the magnetic bead cleaning solution is Tris-HCl buffer solution containing Tween and a preservative; the pre-excitation liquid is a nitric acid solution containing hydrogen peroxide.
As shown in fig. 1, a magnetic rod sleeve for sleeving a magnetic rod is arranged in the hole 0 of the detection reagent strip; a coated antibody magnetic bead is arranged in the No. 3 hole; a labeled reactant is arranged in the No. 6 hole; magnetic bead cleaning liquid is arranged in the No. 7-9 hole sites; a pre-excitation liquid is arranged in the No. 10 hole.
Example 2
This example provides a method for detecting a test strip according to example 1, comprising the steps of:
s1, adding the sample to a No. 4 hole site, simultaneously transferring the coated antibody magnetic beads and the labeled reactant to the No. 4 hole site, and combining the coated antibody magnetic beads and the labeled reactant into an immune complex through immune reaction, wherein the immune complex is a magnetic microsphere coated by an anti-interleukin-6 monoclonal antibody, an interleukin-6 antigen and an anti-interleukin-6 monoclonal antibody labeled with acridinium ester;
s2, transferring the immune complexes to the No. 7-9 hole sites in sequence to remove the unbound antigen or the labeled reactant through washing;
s3, transferring the immune complex to the No. 10 hole site, adding an exciting liquid, and determining the luminous value of the chemiluminescence reaction, wherein the luminous value is in positive correlation with the concentration of interleukin-6 in the sample.
Example 3
This example provides a test kit comprising the test strip of example 1, and further comprising a calibrator.
Wherein the calibrator is BSA solution containing interleukin-6 antigen.
Example 4
This example provides a method for preparing the detection kit as described in example 3, comprising the steps of:
(1) preparation of coated antibody magnetic beads
Dialyzing 1mg of interleukin-6 antibody with PB buffer (pH8.1) at room temperature for no less than 16-24 hr; adding 0.025mg of biotin into the dialyzed antibody, and uniformly mixing; placing the mixed solution in a constant temperature incubator at 25 +/-1 ℃, and standing for reaction for 120 +/-10 min; dialyzing the biotinylated antibody against PB buffer (pH7.4) at room temperature for 16-24 h;
shaking up streptavidin magnetic beads, uniformly mixing all precipitates at the bottom of a container, sucking 20mg of magnetic beads, cleaning twice with a magnetic bead cleaning solution with the volume not less than 2 times that of the magnetic beads, and redissolving the magnetic beads to be not less than 5mg/mL by using an interleukin-6 magnetic bead storage solution; mixing magnetic beads and biotinylated antibodies, wherein the final concentration of the magnetic beads is not lower than 10mg/mL, placing the magnetic beads in a constant-temperature oscillation box at 37 +/-2 ℃, shaking uniformly at 180rmp/min, and reacting for 16-24 h; taking down the reacted magnetic beads, washing the magnetic beads for 4 times by using magnetic bead cleaning solution with the reaction volume not less than 2 times, diluting the magnetic bead solution to 25 mu g/mL by using interleukin-6 magnetic bead preservation solution, and preserving the magnetic bead solution at the temperature of 2-8 ℃ for later use.
(2) Preparation of labeled reactants
Taking 1mg of interleukin-6 labeled antibody, and dialyzing with PB buffer solution (pH8.1) at room temperature for 16-24 h; diluting the dialyzed antibody to 1.0mg/mL by using a PB buffer solution (pH8.1), taking 0.1mg of acridinium ester, and quickly and uniformly mixing the antibody and the acridinium ester; placing the solution in a constant temperature incubator at 25 + -2 deg.C, standing for reaction for 120 + -10 min, and keeping out of the sun during the whole reaction process; purifying with G-50 chromatographic column, diluting the purified acridinium ester labeled antibody with interleukin-6 acridinium ester labeled preservative solution to 60ng/mL, and preserving at 2-8 deg.C for use.
(3) Preparing magnetic bead cleaning solution
At room temperature, 1.212g Tris, 9.0g sodium chloride, 0.4mL HCl, 0.2mL Tween-20, 5.0mL 20% NaN were added to a volume of purified water30.5mL Brij-35, the pH value is detected to be 8.3 +/-0.2 after the uniform mixing, and the volume of the purified water is fixed to 1L.
(4) Preparing pre-exciting liquid
At room temperatureNext, 44mL of H was added to a volume of purified water2O2And 0.55mL of concentrated nitric acid, uniformly mixing, detecting the pH value to be 2.5 +/-0.2, and metering the volume of purified water to 1L.
(5) Preparing interleukin-6 magnetic bead preservation solution
Adding 6.06g Tris, 9.0g sodium chloride and 3.8mL HCl into a certain volume of purified water at room temperature, stirring for at least 5min until complete dissolution, and then adding 1.0mL Tween-20 and 5mL 20% NaN3Finally, slowly adding 10.0g BSA, and stirring for at least 10min until complete dissolution; after all the components are completely dissolved, the pH value is measured to be qualified at 7.2 +/-0.2 by a pH meter, and the volume of purified water is determined to be 1L.
(6) Preparing interleukin-6 acridinium ester mark preserving fluid
Adding 6.06g Tris, 9.0g sodium chloride and 3.8mL HCl into a certain volume of purified water at room temperature, stirring for at least 5min until complete dissolution, and adding 0.2mL Tween-20 and 5mL 20% NaN3Finally, slowly adding 5.0g BSA and 1.0g casein sodium salt, and stirring for at least 10min until complete dissolution; after all the components are completely dissolved, the pH value is measured to be qualified at 7.2 +/-0.2 by a pH meter, and the volume of purified water is determined to be 1L.
(7) Preparation of interleukin-6 calibration substance
Interleukin-6 antigen was formulated with 2% BSA as a standard and lyophilized at concentrations of 10 and 1000pg/mL, respectively.
(8) Assembling: the reagents are assembled into a box and stored at 2-8 ℃.
The detection kit prepared in this example needs to be examined as follows:
(1) physical inspection: the reagent strip is required to be clean by visual observation, no obvious impurity is generated in each hole of the reagent strip, and the sealing film is good; the freeze-dried product is white block or powder with a certain volume and has no obvious other impurities;
(2) the accuracy is as follows: measuring the internal quality control product (L, M, H) at low, medium and high concentrations, respectively, wherein the measured values are within the allowable range;
(3) linearity: the dose-response curve is in the concentration range of 1.5-5000pg/mL, and the absolute value of the correlation coefficient r is not lower than 0.99;
(4) analysis sensitivity: the analysis sensitivity of the kit is not higher than 1.5 pg/mL;
(5) precision: the precision (CV%) of a precision reference product (n is 10) is required to be not higher than 8% by parallel measurement of the same batch of kit; ② the precision reference substance (n is 3 multiplied by 10) is measured in parallel by three different batches of kits with different batch-to-batch differences, the precision (CV%) is required to be not higher than 10%;
(6) stability: the test piece is placed at 37 ℃ for 7 days, and the measured value still meets the requirements.
Example 5
This example provides a method for using the detection kit as described in example 3, and the method, after using the detection instrument of CN107525922A, places the reagent strip in the incubation chamber, includes the following steps:
s1, taking out the reagent, placing the reagent in a room temperature environment in a dark place according to requirements, and if the reagent needs to be taken out, putting the reagent together with a black plastic box;
(if the lot of reagent is used for the first time, the quality control assay is outside the target range, or the same lot of reagent has been used for 28 days, the instrument needs to be calibrated with a calibrator before the assay;
the calibration method comprises the following steps: scanning the calibration card by using an instrument, storing the calibration main curve of the reagent into the instrument, detecting the fully-redissolved calibrator, measuring each calibrator twice, and fitting a new calibration curve again according to the concentration and the luminous value of the calibrator; detecting the quality control product completely redissolved, and judging whether the reagent is controlled according to the target value range of the quality control product; )
S2, placing the sample to be tested on a sample rack, and then placing the sample into the corresponding position of the instrument;
s3, setting an input detection program;
s4, taking a required number of reagent strips, inserting the reagent strips into corresponding channels on the instrument according to screen prompts, and ensuring that the reagent strips are inserted to the bottom without looseness;
s5, clicking a start button on the screen to start detection reaction;
and S6, after the reaction is finished, directly reading the detection result from an instrument interface.
Detection examples
213 clinical samples of interleukin-6 are collected, and the results of synchronous comparison of the kit and the similar products (interleukin 6 detection kit-electrochemiluminescence method, Roche) on the market show that: the correlation coefficient (r) is 0.976, the positive coincidence rate is 98.3%, the negative coincidence rate is 98.9%, and the total coincidence rate is 98.6%.
In summary, the interleukin-6 detection reagent strip of the present invention has at least the following performance advantages:
1) linear range: the detection range of the kit is 1.5-5000 pg/mL;
2) linearity: diluting the sample at the upper limit of the linear range (about 5000pg/mL), and calculating the correlation coefficient of the average value and the dilution ratio as 0.99;
3) HOOK effect: the sample with the concentration less than or equal to 200000pg/mL has no obvious hook effect;
4) methodological alignment: in 213 clinical samples, the kit and the marketed kit are used for testing simultaneously, and correlation coefficient statistics is carried out on the results of the kit and the marketed kit, wherein the correlation coefficient R is 0.976;
5) compared with similar products in the market, the kit has good performance, low cost and higher clinical application value;
6) the disposable magnetic rod sleeve is adopted to prevent the magnetic beads from polluting the magnetic rod and simultaneously facilitate the elution of the magnetic beads;
7) the reaction liquid except the exciting liquid is adopted, so that a liquid path system with a complex instrument is avoided, and the instrument is miniaturized and is easy to maintain;
8) the single-strip single-test detection mode realizes the POCT of the project;
9) the magnetic beads with the particle size of 1.0-1.5 μm are adopted to ensure that the reaction is rapid, and the total time from the sample loading to the result reporting is within 14 minutes;
10) by adopting the heat sealing film technology, the reagent is effectively prevented from being mixed with the holes, and the transportation problem is solved.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (9)
1. The detection reagent strip for the interleukin-6 is characterized by comprising a plurality of hole sites which are arranged side by side; and at least one of a magnetic rod sleeve, a coated antibody magnetic bead, a labeled reactant, a magnetic bead cleaning solution or a pre-excitation solution is arranged in the hole sites and used for sleeving the magnetic rod.
2. The test reagent strip of claim 1, wherein the coated antibody magnetic beads are magnetic microspheres coated with anti-interleukin-6 monoclonal antibodies.
3. The test reagent strip according to claim 1, wherein the labeling reagent is an anti-interleukin-6 monoclonal antibody labeled with acridinium ester.
4. The test strip of claim 1, wherein the bead wash solution is Tris-HCl buffer solution containing tween and a preservative.
5. The test reagent strip of claim 1, wherein the pre-excitation liquid is a nitric acid solution containing hydrogen peroxide.
6. The test reagent strip according to claim 1, wherein a magnetic rod sleeve for sleeving a magnetic rod is arranged in the hole No. 0 of the test reagent strip; a coated antibody magnetic bead is arranged in the No. 3 hole; a labeled reactant is arranged in the No. 6 hole; magnetic bead cleaning liquid is arranged in the No. 7-9 hole sites; a pre-excitation liquid is arranged in the No. 10 hole.
7. A test method using the test reagent strip according to any one of claims 1 to 6, comprising the steps of:
s1, adding the sample to a No. 4 hole site, simultaneously transferring the coated antibody magnetic beads and the labeled reactant to the No. 4 hole site, and combining the coated antibody magnetic beads and the labeled reactant into an immune complex through immune reaction, wherein the immune complex is a magnetic microsphere coated by an anti-interleukin-6 monoclonal antibody, an interleukin-6 antigen and an anti-interleukin-6 monoclonal antibody labeled with acridinium ester;
s2, transferring the immune complexes to the No. 7-9 hole sites in sequence to remove the unbound antigen or the labeled reactant through washing;
s3, transferring the immune complex to the No. 10 hole site, and adding an excitation liquid to determine the luminous value of the chemiluminescence reaction.
8. A test kit comprising the test reagent strip according to any one of claims 1 to 6,
also includes a calibrator.
9. The test kit of claim 8, wherein the calibrator is a BSA solution containing interleukin-6 antigen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111250811.3A CN114217068A (en) | 2021-10-26 | 2021-10-26 | Detection reagent strip for interleukin-6 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111250811.3A CN114217068A (en) | 2021-10-26 | 2021-10-26 | Detection reagent strip for interleukin-6 and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114217068A true CN114217068A (en) | 2022-03-22 |
Family
ID=80696203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111250811.3A Pending CN114217068A (en) | 2021-10-26 | 2021-10-26 | Detection reagent strip for interleukin-6 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114217068A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015165357A1 (en) * | 2014-04-29 | 2015-11-05 | 北京普恩光德生物科技开发有限公司 | Detection kit for interleukin-6 |
| CN107655880A (en) * | 2017-09-21 | 2018-02-02 | 苏州新波生物技术有限公司 | A kind of myoglobins magnetic microparticle chemiluminescence detection kit and its application method |
| CN107677833A (en) * | 2017-09-21 | 2018-02-09 | 苏州新波生物技术有限公司 | A kind of cardiac muscle troponin I magnetic microparticle chemiluminescence measure kit and its application method |
| CN107817354A (en) * | 2017-11-03 | 2018-03-20 | 太原瑞盛生物科技有限公司 | A kind of chemiluminescence detection kit of interleukin 6 and preparation method thereof |
-
2021
- 2021-10-26 CN CN202111250811.3A patent/CN114217068A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015165357A1 (en) * | 2014-04-29 | 2015-11-05 | 北京普恩光德生物科技开发有限公司 | Detection kit for interleukin-6 |
| CN107655880A (en) * | 2017-09-21 | 2018-02-02 | 苏州新波生物技术有限公司 | A kind of myoglobins magnetic microparticle chemiluminescence detection kit and its application method |
| CN107677833A (en) * | 2017-09-21 | 2018-02-09 | 苏州新波生物技术有限公司 | A kind of cardiac muscle troponin I magnetic microparticle chemiluminescence measure kit and its application method |
| CN107817354A (en) * | 2017-11-03 | 2018-03-20 | 太原瑞盛生物科技有限公司 | A kind of chemiluminescence detection kit of interleukin 6 and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108362688B (en) | Detection kit for chemiluminescence of 25-hydroxy vitamin D magnetic particles | |
| CN111735965B (en) | Myocardial troponin I detection reagent, preparation method and myocardial troponin I detection kit | |
| CN107727869A (en) | Kit of antinuclear antibodies and preparation method thereof in a kind of measure serum | |
| CN111289758B (en) | Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP | |
| CN202916286U (en) | Latex enhanced turbidimetric immunoassay kit for quantitatively detecting procalcitonin (PCT) | |
| CN114200132A (en) | Kit for detecting thyroglobulin antibody and subtype thereof | |
| CN113804896A (en) | Magnetic particle chemiluminescence kit for measuring interleukin-8 content in human serum | |
| US3957436A (en) | Resultant color step indicator | |
| JPS62100660A (en) | Immunoassay method of high molecule | |
| CN109297953A (en) | The chemiluminescence determination kit and detection method of C- peptide content in a kind of serum | |
| CN114878825A (en) | C peptide determination kit and method for detecting content of C peptide in human serum | |
| CN113125696A (en) | Estradiol homogeneous phase chemiluminescence detection kit and application thereof | |
| CN108717117A (en) | A kind of vancomycin immunologic function test reagent and its preparation and detection method | |
| CN109085343B (en) | Kit for determining anti-Jo-1 antibody and detection method | |
| CN108362892B (en) | Procalcitonin colloidal gold immunoturbidimetry detection reagent | |
| CN114217068A (en) | Detection reagent strip for interleukin-6 and application thereof | |
| CN111721934A (en) | Improved specific growth factor detection kit and application thereof | |
| CN113125731A (en) | Competitive homogeneous phase chemiluminescence assay kit and application thereof | |
| CN115166229A (en) | Direct chemiluminescence method kit for determining content of neurofilament light chain protein and preparation method thereof | |
| CN115639367A (en) | Chemiluminescence immunoassay kit for detecting anti-keratin antibody IgG and application | |
| CN114487446A (en) | Stable apolipoprotein B determination kit with strong anti-interference capability | |
| CN1287152C (en) | Freeze dried products of colloidal gold for quantitatively detecting human chorionic gonadotrophin and preparing method thereof | |
| CN111537751A (en) | Myocardial troponin I, creatine kinase isoenzyme and myoglobin joint detection kit and detection method | |
| CN113125704A (en) | Homogeneous phase chemiluminescence assay kit and application thereof | |
| CN117288966B (en) | Kit for combined detection of IGF-1 and IGFBP-3 and lysate and buffer solution used by kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220322 |
|
| WD01 | Invention patent application deemed withdrawn after publication |